To me, the obvious benefit to Generex shareholders is that the company is no longer required to raise $20 million cash to complete the Veneto acquisition. Shareholders didn’t exactly like when Generex raised a few million earlier this year to get some monies to Olaregen and Regentys. And the shares used in the new deal all come from the pooled shares of certain insiders including Joe. Joe has sole voting power on all the shares in the pool. So, Generex eliminates the need to dilute our shares via raising $20 million, and also doesn’t dilute our shares via issuing new ones. All the shares in the pool already are outstanding.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links